Pauline Wils

Dr. Pauline Wils

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 December 2020 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PWPauline Wils
Pauline Wils
PSPhilippe Seksik
Philippe Seksik
CSCarmen Stefanescu
Carmen Stefanescu
SNStephane Nancey
Stephane Nancey
MAMatthieu Allez
Matthieu Allez
TGthe PREGNANCY‐GETAID study group
the PREGNANCY‐GETAID study group

Verified
Journal Article
Open access
PDF file
PWPauline Wils
Pauline Wils
BCBénédicte Caron
Bénédicte Caron
Ferdinando D'AmicoFerdinando D'Amico
Ferdinando D'Amico
SDSilvio Danese
Silvio Danese
Laurent Peyrin-birouletLaurent Peyrin-biroulet
Laurent Peyrin-biroulet
Up to 60% of inflammatory bowel disease (IBD) patients experience abdominal pain in their lifetime regardless of disease activity. Pain negatively affects different areas of daily life and particularly impacts the quality of life of IBD patients. This review provides a comprehensive overview of the multifactorial etiology implicated in the chronic abdominal pain of IBD patients including peripheral sensitization by inflammation, coexistent irritable bowel syndrome, visceral hypersensitivity, alteration of the brain–gut axis, and the multiple factors contributing to pain persistence. Despite the optimal management of intestinal inflammation, chronic abdominal pain can persist, and pharmacological and non-pharmacological approaches are necessary. Integrating psychological support in care models in IBD could decrease disease burden and health care costs. Consequently, a multidisciplinary approach similar to that used for other chronic pain conditions should be recommended.

15 February 2023 in Immunotherapy
Verified
Journal Article
Closed access
PWPauline Wils
Pauline Wils
LPLaurent Peyrin-Biroulet
Laurent Peyrin-Biroulet
Sphingosine-1-phosphate (S1P) and its receptor (S1PR) are involved in the pathogenesis of multiple immune-mediated inflammatory disorders, including inflammatory bowel disease. The use of S1PR modu... Plain language summary Etrasimod is a new and promising drug for ulcerative colitis patients. Ulcerative colitis is a chronic inflammatory bowel disease caused by the body's inability to control it... Tweetable abstract In this review, the authors summarize the mechanism of action of etrasimod and provide an update on the available clinical efficacy and safety data regarding etrasimod for the tr...

1 February 2017 in Digestive and Liver Disease
Verified
Journal Article
Closed access
NDNicolas Duveau
Nicolas Duveau
MNMaria Nachury
Maria Nachury
RGRomain Gerard
Romain Gerard
JBJulien Branche
Julien Branche
VMVincent Maunoury
Vincent Maunoury
BPBenjamin Pariente
Benjamin Pariente

10 September 2025 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PWPauline Wils
Pauline Wils
RARomain Altwegg
Romain Altwegg
ABAnthony Buisson
Anthony Buisson
LVLucine Vuitton
Lucine Vuitton
SNStephane Nancey
Stephane Nancey
G(Groupe D‘eTude Thérapeutique Des Affections Inflammatoires du Tube Digestif (Getaid)
Groupe D‘eTude Thérapeutique Des Affections Inflammatoires du Tube Digestif (Getaid)
Background and Aims: While this strategy is frequently used for other biologics, real-world evidence on subcutaneous (SC) vedolizumab (VDZ) dose intensification in inflammatory bowel disease (IBD) is lacking. This study aimed to assess the effectiveness and safety of SC VDZ intensification. Methods: We conducted a retrospective study in 25 centers including all patients with active ulcerative colitis (UC) or Crohn’s disease (CD) (defined by PRO2), and incomplete or loss of response to SC VDZ 108 mg every other week (EOW) when the drug was intensified. The primary outcome was steroid-free clinical response (SFCr) defined by at least 50% of PRO2 improvement, no treatment change, no surgery, and SC VDZ persistence at 3 months. Results: Of the 154 included patients (66% UC, 34% CD), prior anti-tumor necrosis factor (anti-TNF) exposure was reported in 85% of CD and 50% of UC patients. SC VDZ was intensified for an incomplete response in 73% of CD and 53% of UC patients, mostly at 108 mg weekly (95%). At 3 months, SFCr was achieved in 35% of CD and 43% of UC patients. In multivariate analysis, factors associated with response were secondary loss of response in CD, and prior anti-TNF exposure in UC. At 12 months, 51% of CD and 37% of UC patients maintained SC VDZ. Adverse events occurred in 10 patients including one severe pneumonia and one angioedema. Conclusions: In this real-world study evaluating SC VDZ intensification, an SFCr was observed in at least one-third of IBD patients at 3 months, suggesting the benefit of this strategy in clinical practice.

21 February 2025 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
PWPauline Wils
Pauline Wils
MKMohammad Reza Habibi Kavashkohie
Mohammad Reza Habibi Kavashkohie
FGFabiana Sélos Guerra
Fabiana Sélos Guerra
SLSéverine Landais
Séverine Landais
MRManuel Rubio
Manuel Rubio
LCLaurence Chapuy
Laurence Chapuy
Background and Aims: Innate immune cells, including dendritic cells (DCs), monocytes (Mono), macrophages (Mac), natural killer (NK), and innate lymphoid cells (ILC), contribute to chronic inflammation in lymphoid tissues. Here, we characterized the innate immune cell landscape in inflamed mesenteric lymph nodes (MLNs) of patients with inflammatory bowel diseases (IBD) at the single-cell level. Methods: Surgically resected colonic MLNs were obtained from patients with Crohn’s disease (CD; n = 3), ulcerative colitis (UC; n = 3), non-inflamed UC (n = 1), and non-IBD (n = 2). CD45+CD3−CD19− non-T/non-B cells were FACS-sorted to capture rare innate immune cells. Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) was performed on the BD Rhapsody platform alongside multiparameter flow cytometry staining. Results: CITE-seq analysis unveiled the molecular signature of 11 Mono/Mac/DC (MMDC) and 7 NK/ILC enriched clusters in human MLNs. DC clusters included 3 newly characterized DC clusters such as CD1c/CD163/VCAN/CD64-expressing DC3; AXL-expressing DCs; and a CD103+ DC subset, expressing LTB, S100B, and IL22RA2 (encoding IL22BP). Mono/Mac clusters comprised inflammatory monocytes, which accumulated in IBD compared to non-IBD MLNs. Among NK/ILC clusters, we identified a cytotoxic ILC subset (IL7R, KLRD1, GNLY), previously not reported in MLNs, reminiscent of cytotoxic ILC1-like cells found in inflamed gut mucosa. Conclusion: CITE-seq and flow-cytometry analyses of colonic MLNs from patients with active IBD reveal the molecular signature and cell distribution of previously uncharacterized DC and ILC subpopulations in human MLNs. These findings expand our understanding of immune responses during chronic inflammation in IBD.